Cell/Gene Tx channel feed

FDA's Pe­ter Marks talks re­im­burse­ment of gene ther­a­pies that win ac­cel­er­at­ed ap­proval

3 years ago

SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

3 years ago
Startups
Deals

Gilead woos Cindy Perettie from Roche to lead Kite af­ter Christi Shaw de­parts

3 years ago
People

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

3 years ago
Startups
Deals

On a per­son­al mis­sion for his daugh­ter, Paul Bres­ge launch­es an­oth­er eye dis­ease biotech with $100M for Ray Ther­a­peu­tics

3 years ago
Financing
Startups

Gra­cell gives sneak peek in­to leukemia CAR-T cell pro­gram ahead of EHA

3 years ago
R&D

AAV pro­duc­er New­Bi­ologix emerges from stealth with $50M Se­ries A

3 years ago
Pharma
Manufacturing

New blood and cell ther­a­py-fo­cused ven­ture fund emerges with $50M and a Jen­nifer Doud­na spin­out in tow

3 years ago
Financing
Startups

Up­dat­ed: FDA re­port rais­es con­cerns over Sarep­ta Duchenne gene ther­a­py ahead of ac­cel­er­at­ed ap­proval de­ci­sion

3 years ago
FDA+

George Scan­gos joins Voy­ager board in re­union with Bio­gen col­league Al San­drock

3 years ago
People

As­cend launch­es with $130M+ as it looks to build in the AAV space

3 years ago
Manufacturing

CRISPR uni­corn Mam­moth backs off di­ag­nos­tics re­search, lay­ing off 35 on test­ing team to fo­cus on ther­a­peu­tics

3 years ago
Startups

As­traZeneca en­ters pre­clin­i­cal cell ther­a­py deal with Cana­di­an biotech

3 years ago
Deals

‘Un­be­liev­ably im­por­tant mo­ment’: Sarep­ta clears the air on man­u­fac­tur­ing, pay­ers ahead of gene ther­a­py ad­comm

3 years ago
FDA+

Im­mat­ics spikes on a round of promis­ing — but still ear­ly — au­tol­o­gous cell ther­a­py da­ta for sol­id tu­mors

3 years ago
R&D

Bris­tol My­er­s' CAR-T Breyanzi hits end­points in two lym­phoma stud­ies

3 years ago
R&D
Pharma

Mile­stone Mon­day for Im­mat­ics’ Bris­tol My­ers-al­lied cell ther­a­py and 2sev­en­ty bio’s No­vo-part­nered he­mo­phil­ia A work

3 years ago
Financing
Pharma

Celu­lar­i­ty ends clin­i­cal tri­al, to now fo­cus on new NK cell ther­a­py amid cash crunch

3 years ago
R&D

Sang­amo cuts 120 jobs, an­nounces pri­or­i­tized pipeline to ex­tend cash run­way an­oth­er year

3 years ago

CAR-T re­shaped can­cer treat­ment. Can it change au­toim­mune dis­ease, too?

3 years ago
In Focus

With $270M, Beam spin­off Or­bital Ther­a­peu­tics builds RNA med­i­cines as it hunts for part­ners, more de­liv­ery tech 

3 years ago
Financing
Startups

Up­dat­ed: Bio­gen chops cer­tain stroke and RNA ther­a­py pro­grams as it con­tin­ues R&D re­vamp

3 years ago
R&D

On Ver­tex and CRISPR Ther­a­peu­tics’ heels, blue­bird sub­mits sick­le cell gene ther­a­py to FDA

3 years ago
R&D
FDA+

Leg­end rais­es $200M from pri­vate in­vestor af­ter con­fer­ence leaks PhI­II Carvyk­ti da­ta

3 years ago
Financing
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times